OM:SUS
OM:SUSMedical Equipment

Why Surgical Science Sweden (OM:SUS) Is Down 54.0% After Intuitive Cancels Key Licensing Agreement

In late November 2025, Surgical Science Sweden AB announced that Intuitive canceled their Memorandum of Understanding and shifted back to their prior agreement, with the company warning it will not meet its previously stated 2026 financial targets. This decision is projected to reduce Surgical Science Sweden’s license revenues by approximately SEK 60–90 million in 2026, highlighting the company’s exposure to fluctuations in large partner relationships. To assess the impact of Intuitive’s...
OM:BEIA B
OM:BEIA BMachinery

European Equity Opportunities That May Be Undervalued In November 2025

As European markets grapple with concerns over inflated AI stock valuations and the impact of U.S. interest rate expectations, the pan-European STOXX Europe 600 Index has seen a decline, reflecting broader market unease. In this environment, identifying potentially undervalued stocks can be crucial for investors looking to capitalize on opportunities that may offer value amidst prevailing economic uncertainties.
OM:VITR
OM:VITRBiotechs

European Stocks Possibly Priced Below Intrinsic Value Estimates

Amid recent fluctuations in global markets, European stocks have faced pressure from concerns over AI valuations and shifting interest rate expectations. Despite these challenges, the expansion of business activity in the eurozone suggests potential opportunities for investors seeking stocks that may be priced below their intrinsic value estimates. Identifying such stocks often involves assessing fundamental factors like earnings potential and market positioning relative to current economic...
OM:EKTA B
OM:EKTA BMedical Equipment

Elekta (OM:EKTA B) Margins Fall to 1.7%, Underscoring Profitability Concerns vs. Bullish Growth Forecasts

Elekta (OM:EKTA B) just posted its Q2 2026 results, reporting revenue of SEK 4.1 billion and basic EPS of 0.60 SEK for the quarter, with net income reaching SEK 230 million. The company has seen revenue fluctuate over recent quarters, ranging from SEK 3.6 billion to SEK 5.2 billion. EPS has swung from -1.01 SEK to 0.89 SEK since the beginning of 2025. Margins continue to reflect a mixed earnings picture, keeping investor focus firmly on profit trends and sector benchmarks. See our full...
OM:VSURE
OM:VSURECommercial Services

Verisure (OM:VSURE) Revenue Growth Outpaces Market but Net Losses Persist, Challenging Profitability Narratives

Verisure (OM:VSURE) just posted its Q3 2025 numbers, delivering €933 million in revenue with basic EPS at -€0.06. Over the past year, the company has seen revenue grow from €854 million to €933 million, while EPS figures have stayed negative across multiple quarters. Despite compressed margins and ongoing unprofitability, investors are watching closely as growth forecasts remain upbeat from this point forward. See our full analysis for Verisure. Now let’s see how these figures compare to the...
OM:DORO
OM:DOROTech

Doro (OM:DORO) Net Margin Reaches 7.4%, Reinforcing Bullish Profitability Narrative

Doro (OM:DORO) has posted its third-quarter 2025 results, revealing revenue of 247.7 million SEK and basic EPS of 0.90 SEK, with net income at 21.9 million SEK. Over the past several quarters, the company has seen revenue climb from 206.7 million SEK in Q2 2024 to 247.7 million SEK in the latest quarter. EPS moved from 0.58 SEK to 0.90 SEK. Margins have remained solid, marking a stretch of steady profitability that investors will be parsing for what comes next. See our full analysis for...
OM:VO2
OM:VO2Capital Markets

Discover 3 European Penny Stocks With Market Caps Over €40M

Amidst renewed worries about inflated AI stock valuations and receding expectations for a U.S. interest rate cut, European markets have seen a downturn, with major indices such as the STOXX Europe 600 Index experiencing declines. Despite these challenges, investors continue to explore opportunities in the market's less prominent corners. Penny stocks, often representing smaller or newer companies, remain an intriguing area for those seeking growth potential at lower price points. In this...
OM:GETI B
OM:GETI BMedical Equipment

Getinge (OM:GETI B): Is There More Value Ahead After a Strong Year for Shareholders?

Getinge (OM:GETI B) shares have continued to move in day-to-day trading, capturing investor attention as the healthcare equipment supplier’s stock has seen a mix of short-term ups and downs throughout the past month. See our latest analysis for Getinge. Getinge’s share price has been on a rollercoaster lately, but zooming out, momentum is firmly with shareholders. The stock has delivered an impressive 16.4% share price return year-to-date, while total shareholder return over the past year...
OM:HPOL B
OM:HPOL BChemicals

European Dividend Stocks To Enhance Your Portfolio

Amid renewed concerns over inflated AI stock valuations and receding expectations for a U.S. interest rate cut, European markets have experienced notable declines, with the STOXX Europe 600 Index dropping by 2.21%. Despite this downturn, the eurozone's business activity continues to expand steadily, providing a backdrop for investors seeking stability through dividend stocks. In such a climate, choosing stocks that offer consistent dividends can be an effective strategy to enhance portfolio...
OM:EKTA B
OM:EKTA BMedical Equipment

Elekta (OM:EKTA B): Assessing Valuation as Profits Climb Despite Lower Sales in Latest Results

Elekta (OM:EKTA B) just released its latest earnings for the second quarter and first half of 2025. While sales dipped compared to last year, investors are paying attention to the company's higher profit and earnings per share. See our latest analysis for Elekta. While Elekta’s recent earnings reveal profits are up even as sales slip, the market remains cautious, as seen in a challenging year-to-date share price return of -27.93%. Over the past year, total shareholder return sits at -26.04%,...